{"id":108283,"date":"2022-11-02T16:13:12","date_gmt":"2022-11-02T21:13:12","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=108283"},"modified":"2022-11-07T17:57:43","modified_gmt":"2022-11-07T22:57:43","slug":"fmcsa-pre-employment-previous-employer-records-checks-for-drug-and-alcohol-program-violations-changes-on-1-6-2023","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/fmcsa-pre-employment-previous-employer-records-checks-for-drug-and-alcohol-program-violations-changes-on-1-6-2023\/","title":{"rendered":"FMCSA Pre-employment\u00a0Previous Employer Records Checks for Drug and Alcohol Program Violations\u00a0Changes on 1\/6\/2023"},"content":{"rendered":"\n

Beginning January 6, 2023, a pre-employment Clearinghouse query will satisfy the requirement to investigate a prospective driver’s previous drug and alcohol program violations, as established by 49 CFR 391.23(e). <\/p>\n\n\n\n

Employers of CDL drivers are required to conduct background investigations before hiring a driver. This process includes determining if the driver has violated the drug and alcohol regulations of any Department of Transportation (DOT) mode within the past three years (see 49 CFR 391.23(e)). Currently, this requires employers or their designated consortia\/third-party administrators (C\/TPAs) to conduct both electronic queries in the Clearinghouse and manual inquiries with previous employers to meet the three-year time frame.<\/p>\n\n\n\n

Beginning January 6, 2023, when three years of violation data is stored in the Clearinghouse, prospective employers must not conduct manual inquiries. In accordance with \u00a7\u00a7 382.413(b) and 391.23(e)(4), beginning January 6, 2023, <\/strong>prospective employers must conduct a pre-employment query of the Clearinghouse, as set forth in \u00a7 382.701(a), to comply with the inquiry requirement in \u00a7 391.23(e) as it pertains to FMCSA-regulated employers.<\/p>\n\n\n\n

NOTE: <\/strong>The Clearinghouse contains only information about drivers employed by FMCSA-regulated employers. If a prospective employee was employed by an employer regulated by a DOT agency other than FMCSA (such as the Federal Railroad Administration, Federal Transit Administration, Federal Aviation Administration, etc.) during the three-year time frame, prospective employers will still be required to directly request drug and alcohol violation information from those DOT-regulated employers in accordance with 391.23(e)(4)(ii), since this information is not reported to the Clearinghouse.<\/p>\n\n\n\n

Annual query requirements have not changed.<\/strong><\/h3>\n\n\n\n

Employers of CDL drivers must conduct a query in the Clearinghouse at least once a year for each CDL driver they employ (see \u00a7\u2009382.701(b)). This annual query requirement applies on a rolling 12-month basis, which means that if you conducted your last annual queries in December 2021, it is time to conduct the next round of annual queries.<\/p>\n\n\n\n

Employers must obtain general consent from CDL drivers they employ before conducting limited queries in the Clearinghouse to view these drivers\u2019 information (you can download a sample limited query consent form<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"

Beginning January 6, 2023, a pre-employment Clearinghouse query will satisfy the requirement to investigate a prospective driver’s previous drug and alcohol program violations, as established by 49 CFR 391.23(e).  Employers of CDL drivers are required to conduct background investigations before hiring a driver. This process includes determining if the driver has violated the drug and alcohol regulations of any Department of Transportation (DOT) […]<\/p>\n","protected":false},"author":2,"featured_media":108285,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"51074,105081,54958,51406,51332,51486","_relevanssi_noindex_reason":"","footnotes":""},"categories":[68,69],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/108283"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=108283"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/108283\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/108285"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=108283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=108283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=108283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}